Efficacy, Tolerance, and Safety of a Novel Botanical Anti‐Inflammatory Moisturizer in Rosacea: Results From a Double‐Blinded, Randomized Controlled Trial
Journal of Cosmetic Dermatology · 2026-05 · 25 (5)
DOI: 10.1111/jocd.70910 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 20.05.2026. Verfasst von Zoe Diana Draelos. Beteiligte Einrichtung: Dermatology Consulting Services, PLCC, High Point, North Carolina, USA. Hauptthemen laut MEDLINE: Rosacea, Anti-Inflammatory Agents, Avena, Aloe. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crescel.
Abstract (Originalsprache)
Background
Rosacea is characterized by facial erythema that can be resistant to improvement.
Aims
This research evaluated the efficacy and tolerability of a topical anti‐inflammatory moisturizer containing oat and aloe as compared to 0.75% metronidazole cream over 12 weeks.
Methods
This double‐blinded, randomized, controlled trial enrolled 60 adults with mild‐to‐severe rosacea, randomized to either the study anti‐inflammatory moisturizer or 0.75% metronidazole cream daily for 12 weeks. Participants were evaluated at baseline and Weeks 4, 8, and 12. Efficacy was measured by investigator global assessment (IGA) of erythema and inflammatory lesion counts. Tolerability was assessed by the investigator and subjects.
Results
Both study products demonstrated similar IGA scores at Week 4. By Week 8, the study oat and aloe anti‐inflammatory moisturizer demonstrated significantly greater reduction in both erythema IGA (50% vs. 22%, p = 0.001) and lesion counts (74% vs. 6%, p = 0.015). At the conclusion of the 12‐week study, the anti‐inflammatory moisturizer produced a reduction in IGA erythema of 54% vs. 23% ( p < 0.001) and a reduction in inflammatory lesion counts of 74% vs. 17% ( p = 0.044). No tolerability issues were noted.
Conclusions
The oat and aloe anti‐inflammatory moisturizer was superior and outperformed 0.75% metronidazole cream in both erythema and lesion reduction in rosacea subjects after 8 and 12 weeks of treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermatology Consulting Services, PLCC, High Point, North Carolina, USA.
ORCID-Profile: Zoe Diana Draelos
Förderung
- Crescel
Zitieren
APA
Draelos, Z. D. (2026). Efficacy, Tolerance, and Safety of a Novel Botanical Anti‐Inflammatory Moisturizer in Rosacea: Results From a Double‐Blinded, Randomized Controlled Trial. Journal of Cosmetic Dermatology, 25(5). https://doi.org/10.1111/jocd.70910
Vancouver
Draelos ZD. Efficacy, Tolerance, and Safety of a Novel Botanical Anti‐Inflammatory Moisturizer in Rosacea: Results From a Double‐Blinded, Randomized Controlled Trial. Journal of Cosmetic Dermatology. 2026;25(5). doi:10.1111/jocd.70910
BibTeX
@article{Draelos2026,
author = {Draelos, Zoe Diana},
title = {Efficacy, Tolerance, and Safety of a Novel Botanical Anti‐Inflammatory Moisturizer in Rosacea: Results From a Double‐Blinded, Randomized Controlled Trial},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
volume = {25},
number = {5},
doi = {10.1111/jocd.70910}
}
EUVIMED